Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(4.24)
# 399
Out of 5,084 analysts
146
Total ratings
52.27%
Success rate
14.84%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Overweight | $200 → $150 | $16.35 | +817.43% | 7 | Dec 2, 2025 | |
| DMAC DiaMedica Therapeutics | Initiates: Overweight | $25 | $8.78 | +184.90% | 1 | Nov 14, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Overweight | $120 → $200 | $101.29 | +97.45% | 1 | Nov 6, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $85 → $95 | $69.18 | +37.32% | 6 | Nov 5, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $15 → $30 | $2.59 | +1,058.30% | 3 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $100 → $110 | $73.43 | +49.81% | 13 | Oct 30, 2025 | |
| NUVL Nuvalent | Initiates: Overweight | $135 | $109.41 | +23.39% | 1 | Oct 15, 2025 | |
| IVVD Invivyd | Initiates: Overweight | $10 | $2.24 | +347.43% | 1 | Oct 6, 2025 | |
| RNA Avidity Biosciences | Maintains: Outperform | $70 → $65 | $71.77 | -9.43% | 6 | Sep 22, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $43.45 | +72.63% | 5 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $20.09 | - | 3 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $26.57 | -5.89% | 4 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $8 | $3.33 | +140.60% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $13.53 | +84.77% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 → $6 | $5.86 | +2.39% | 2 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $280 | $205.00 | +36.59% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.36 | +274.25% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $3.40 | +488.24% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $231.00 | -6.93% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.28 | +119.78% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.80 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $9.67 | +210.24% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.85 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.23 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $47.10 | +91.08% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.72 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $204.57 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $61.25 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.05 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.65 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $67.56 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.66 | +2,187.63% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $44.91 | +44.73% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $8.61 | -41.93% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $3.29 | +234.86% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $155.33 | -16.31% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $720.28 | +5.51% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $26.71 | -43.84% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $10.52 | +422.81% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.03 | +1,381.48% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.14 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $13.08 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $576.49 | -56.63% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $102.57 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $81.45 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $4.29 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $21.08 | +4.36% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $18.63 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $53.23 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $226.60 | -58.08% | 1 | Aug 17, 2017 |
Janux Therapeutics
Dec 2, 2025
Maintains: Overweight
Price Target: $200 → $150
Current: $16.35
Upside: +817.43%
DiaMedica Therapeutics
Nov 14, 2025
Initiates: Overweight
Price Target: $25
Current: $8.78
Upside: +184.90%
Palvella Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $120 → $200
Current: $101.29
Upside: +97.45%
Mirum Pharmaceuticals
Nov 5, 2025
Maintains: Overweight
Price Target: $85 → $95
Current: $69.18
Upside: +37.32%
Cabaletta Bio
Oct 31, 2025
Maintains: Overweight
Price Target: $15 → $30
Current: $2.59
Upside: +1,058.30%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $100 → $110
Current: $73.43
Upside: +49.81%
Nuvalent
Oct 15, 2025
Initiates: Overweight
Price Target: $135
Current: $109.41
Upside: +23.39%
Invivyd
Oct 6, 2025
Initiates: Overweight
Price Target: $10
Current: $2.24
Upside: +347.43%
Avidity Biosciences
Sep 22, 2025
Maintains: Outperform
Price Target: $70 → $65
Current: $71.77
Upside: -9.43%
CG Oncology
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $43.45
Upside: +72.63%
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $20.09
Upside: -
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $26.57
Upside: -5.89%
Aug 8, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $3.33
Upside: +140.60%
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $13.53
Upside: +84.77%
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $5.86
Upside: +2.39%
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $205.00
Upside: +36.59%
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $13.36
Upside: +274.25%
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $3.40
Upside: +488.24%
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $231.00
Upside: -6.93%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.28
Upside: +119.78%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.80
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $9.67
Upside: +210.24%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $10.85
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.23
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $47.10
Upside: +91.08%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.72
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $204.57
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $61.25
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.05
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.65
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $67.56
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.66
Upside: +2,187.63%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $44.91
Upside: +44.73%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $8.61
Upside: -41.93%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $3.29
Upside: +234.86%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $155.33
Upside: -16.31%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $720.28
Upside: +5.51%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $26.71
Upside: -43.84%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $10.52
Upside: +422.81%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $2.03
Upside: +1,381.48%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.14
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $13.08
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $576.49
Upside: -56.63%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $102.57
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $81.45
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $4.29
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $21.08
Upside: +4.36%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $18.63
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $53.23
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $226.60
Upside: -58.08%